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ABSTRACT
Objective: To evaluate the effectiveness of sildenafil (Viagra) in the treatment of male erectile
dysfunction in Nairobi.
Design: Prospective open label extension study.
Setting: Urology clinics at the Nairobi Hospital, Kenyatta National Hospital and the author's
private clinic in Hurlingham, Nairobi.
Participants: Two hundred and nineteen adult male patients with erectile dysfunction.
Results: The age range was 33-80 years with a mean of 62.5 years and a peak incidence in the
60-69 year age group. One hundred and nineteen patients (54.34%) had organic causes, 85
patients (38.81%) had pyschogenic causes and 15 patients had mixed causes. Two hundred
patients (91.32%) had improved sexual function after treatment with viagra. This improvement
was sustained during the study period of sixteen weeks and included improved erectile and
orgasmic functions and overall sexual satisfaction. One hundred and fifty seven of these
patients responded to therapy with 50mg of viagra; 40 patients with 25mg and three patients
with 100mg of therapy. Nineteen patients (8.68%) had no improvement in sexual function
after viagra administration. Seven patients (3.2%) had adverse effects which were mild and
transient. They included mild headaches in three patients, mild dyspepsia in two patients and
facial flushing and nausea and vomiting in one patient, respectively.
Conclusion: Oral sildenafil (Viagra) is an effective well tolerated and simple treatment for
male erectile dysfunction in the majority of cases. The cost of treatment at about ten United
States  dollars for the 50mg tablet is prohibitive and may limit its wide use by many deserving
patients in this locality.
INTRODUCTION
Erectile dysfunction is the persistent inability to
achieve and maintain an erection sufficient for satisfactory
sexual performance(1). Traditionally this condition has
been called impotence, but the term erectile dysfunction is
more precise because it refers specifically to the clinical
problem of an erection. Furthermore, men with erectile
dysfunction usually retain other sexual functions such as
sexual desire and the ability to achieve orgasm and
ejaculation. Although regarded as a benign condition,
erectile dysfunction has a profound impact on the quality
of life of many men(2). It is estimated that it affects upto
30 million men in the United States and is age-associated
with estimated prevalence rates of 39% among men 40
years old and 70% among those over 70 years old(3). In
this locality, although no epidemiological study similar to
the Massachusetts male ageing study has been carried out,
erectile dysfunction is presumed to be common. However,
until recently, most patients did not consult the medically
trained doctors. They preferred to consult the traditional
medical practitioners because of the stigma and socio-
cultural taboos associated with erectile dysfunction.
It was once thought to be a primarily psychological
and lifestyle disorder. More recently it has become clear
that erectile dysfunction is often attributed to organic
disease(4-7). Damage to arteries, smooth muscle and
fibrous tissue resulting in altered blood flow to and from
the penis are the most common causes(2). This is often the
result of chronic disease such as diabetes, kidney disease,
artherosclerosis, and vascular disease(8,9). The results of
the Massachusetts male ageing study, a large population
based random sample study confirmed that erectile
dysfunction is highly correlated with such disease as
hypertension, heart disease and diabetes mellitus(3). The
available methods of treatment include vacuum constriction
devices(10,11), intracavernosal injection of vasoactive
substances including alprostadil (prostaglandin El)(12),
transurethral delivery of alprostadil(13), implantation of
penile prostheses, venous or arterial surgery(15,16) and
psychotherapy.
Normal penile erection depends on the relaxation of
smooth muscles in the corpora cavernosa. In response to
sexual stimuli, cavernous nerves and endothelial cells
release nitric oxide which stimulates the formation of
cyclic guanosine monophosphate(c-GMP) by guanilate
cyclase(17). The mechanism by which cyclic GMP
stimulates the relaxation of smooth muscle remains to be
elucidated(18). Sildenafil (Viagra) is a selective inhibitor
of cyclic GMP specific phosphodiasterase type 5, the
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predominant isoenzyme metabolising cyclic GMP in the
corpus cavenosum. By selectively inhibiting cyclic GMP
catabolism in cavernosal smooth muscle cells, sildenafil
would be expected to restore the natural erectile response
to sexual stimulation but not cause erections in the absence
of such stimulation(19,20). Currently in this locality, no
effective and affordable oral therapy for erectile dysfunction
is widely available. It is against this background that a
prospective open label extension study on the efficacy of
oral sildenafil (Viagra) in the treatment of male erectile
dysfunction in this locality was carried out.
MATERIALS AND METHODS
This is a prospective open label extension study of two
hundred and nineteen male patients with erectile dysfunction. At
the first visit during evaluation informed consent was obtained
from all patients. A detailed general medical history was obtained
followed by sexual history. Sexual function was established
using a sexual function questionnaire which was completed by
each patient answering from the 15 question international index
of erectile dysfunction (IIEF), a validated multidimensional self-
administered questionnaire used for the clinical assessment of
erectile dysfunction and treatment outcomes in clinical
studies(21). Patients were also asked about the existence of
additional systemic diseases and any drugs used. They were also
asked about heart disease and whether or not they were on nitrate
therapy. Complete physical examination including neurological
examination was performed on all patients by the same
investigator. Routine blood chemistry and haematological
laboratory tests and urinalysis were performed on every patient.
Special investigations such as colour doppler ultrasound of the
penis were performed only if clinically indicated as is the
practice by the investigator. Patients were excluded from the
study if they had anatomical deformities of the penis, a primary
diagnosis of premature ejaculation, had uncontrolled diabetes
mellitus, on nitrate therapy or had erectile dysfunction of less
than four months duration.
The men were instructed to take 50mg, 25mg or l00mg of
sildenafil (Viagra) orally approximately one hour before the
planned sexual activity but not more than once every 24 hours.
Patients were reviewed at the outpatient urology clinics at four
weekly intervals for sixteen weeks by the same investigator.
During this period each patient had at least twelve tablets of
viagra. At each visit the patients reported on their responses
regarding erectile function, orgasmic function and overall sexual
satisfaction. The patients were also examined and asked about
any adverse effects during the administration of sildenafil. The
assessment of efficacy was effected by using patient responses
to question 3 (frequency of vaginal penetration) and question 4
(maintenance of erection after penetration) of the 15 question
IIEF questionnaire(21). All relevant data collected were analysed
and tabulated.
RESULTS
A total of 250 patients were seen at the urology clinics
by the same investigator but only 219 of them satisfied the
inclusion criteria for this study on the efficacy of sildenafil
in the treatment of erectile dysfunction undertaken between
November 1998 and August 1999 in Nairobi, Kenya. One
hundred of the patients were referred by other health
practitioners including pharmacists but the majority (150
patients) came directly to the investigator as a result of the
massive publicity given to sildenafil in the local press
since its launch on 31st October 1998.
The age range was 33-80 years with a mean of 62.5
years (Table 1). The causes of erectile dysfunction are
illustrated in Table 2 with organic causes in 119 patients
(54.34%), psychogenic causes in 85 patients (38.81%)
and mixed causes in 15 patients (6.85%). A detailed
distribution of organic causes of erectile dysfunction is
illustrated in Table 3.
Table 1
Age distribution in erectile dysfunction in Nairobi
Age group in years No. of patients % of total
30 - 39 5 2.28
40 - 49 25 11.41
50 - 59 69 31.51
60 - 69 99 40.20
70 - 79 19 8.67
80- 89 2 0.91
Table 2
Causes of erectile dysfunction in Nairobi
Causes of dysfunction No. of patients % of total
Organic causes 19 54.34
Psychogenic causes 85 38.81
Mixed causes 15 6.85
Table 3
Organic causes of erectile dysfunction in Nairobi (n= 119)
Causes of erectile dysfunction No. of % of
patients total
Cardiovascular (controlled hypertension on
antihypertensive therapy e.g. calcium channel brokers) 38 31.93
Cardiovascular (uncontrolled hypertension
diagnosed by the surgeon) 19 15.97
Diabetes mellitus 20 16.81
Other endocrine disorders 3 2.52
Chronic alcoholism 4 3.36
Excessive tobacco consumption 5 4.20
Other prescription drugs (e.g. antiandrogens,
cimetidine, NSAIDS etc) 9 7.56
Non prescription drugs (e.g. antihistamines) 2 1.68
Prostate surgery (TURP and open prostatectomy) 11 9.24
Radical pelvic surgery (e.g. abdominoperineal
excision of rectum). 3 2.52
Spinal cord injury 4 3.36
Neurological disorders 1 0.84
The effective sildenafil dose variation indicated in
Table 4 indicated that the dose of 50mg was effective in
157 patients (71.69%) compared to 25mg and 100mg
which were effective in 40 patients (18.26%) and three
patients (1.37%), respectively. A total of 200 patients had
improved erectile function, 198 had improved orgasmic
function and 200 patients had improved overall sexual
satisfaction indicating an efficacy rate of 91.32% as shown
in Tables 4 and 5. No improvement in erectile function,
orgasmic function and overall sexual satisfaction was
reported in 19 patients respectively (8.68%).
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Table 6
Adverse effects of sildenafil administration
Adverse effect Number of patients % of total
Mild headaches 3 1.37
Mild dyspepsia 2 0.91
Nausea and vomiting 1 0.46
Facial flushing 1 0.46
Seven patients (3.2%) had adverse effects related to
viagra administration (Table 6). The adverse effects include
mild headaches in three patients, dyspepsia in two patients
and facial flushing, and nausea and vomiting in one patient,
respectively. All the adverse effects were mild and transient
and no patient discontinued treatment because of them. No
patient experienced visual disturbances, myalgia or priapism.
DISCUSSION
The oral administration of drugs is known to be the
easiest and most acceptable form of treatment for male
erectile dysfunction compared with other successful
modalities such as external vacuum devices, topical creams,
intracavernosal injection and intraurethral application of
vasoactive drugs and different penile reconstructive
vascular and prosthetic surgical techniques developed
over the last three decades(22). Unfortunately, until
recently, yohimbine hydrochloride was the most widely
Table 4
Effective sildenafil dose response variation in the treatment of male erectile dysfunction
Dosage No. of patients No. of No. of non % of % of non
given responses responses responses responses
25mg 60 40 20 66.67 33.33
50mg 159 + (20 non
responders to
25mg)= 179 157 22 87.71 12.29
100mg 22 (all non
responders to
25mg and 50mg) 3 19 13.64 86.64
Total for all doses
(25,50  and 100MG) 219 200 19 91.32 8.68
Table 5
Effect of (sildenafil) viagra administration on sexual function of men with erectile dysfunction
Effect of viagra administration Number of patients % of total
Improved erectile function 200 91.32
Improved orgasmic function 198 90.41
Intercourse satisfaction 199 90.87
Improved overall sexual satisfaction 200 91.32
No improvement in erectile, function orgasmic
function and overall sexual satisfaction 19 8.68
used oral medication for erectile dysfunction, but the
outcome has been disappointing even when used in high
doses(23). Currently, there is a worldwide increase in the
prevalence of male erectile dysfunction which is associated
with rapidly ageing populations. The newly available and
highly publicised oral medical treatments such as sildenafil
and vasomax  are now raising challenging policy issues in
many countries including Kenya(24). The results of clinical
studies on a selective 5- phosphodiasterase inhibiting
sildenafil (Viagra) have particularly continued to be
promising and form the basis of this study(25).
The age range was 33-80 years with a mean of 62.5
years and a peak incidence in the 60-69 year age group.
The number of men with erectile dysfunction increased
steadily with age from five (2.28%) in the 30-39 year age
group to 99 (40.20%) in the 60-69 year age group (Table
1). These findings are similar to previous reports in the
Massachussetts male ageing study in which strong
association between age and male erectile dysfunction
was observed(3,26). The apparent decrease in the number
of patients with erectile dysfunction in the 70-79 year age
group in this locality is because of reduced life expectancy
resulting in reduced numbers in this age group.
One hundred and nineteen patients (54.34%) had
organic causes for the erectile dysfunction, eighty five
patients (38.81%) had pyschogenic causes and fifteen
patients (6.85%) had mixed causes. The distribution of the
various organic causes is illustrated in Table 2.
The responses of individual patients to sildenafil
administration is illustrated in Tables 4 and 5. Sixty
patients were placed on 25mg of sildenafil. At the end of
four weeks, 40 patients (66.67%) had shown improvement
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in sexual function. These consisted of improved erectile
function as indicated by achieving and sustaining an
erection sufficient for vaginal penetration; and maintaining
the erection after penetration; improvement in orgasmic
function, and improvement in overall sexual satisfaction.
Treatment was continued for sixteen weeks for the 40
responders but discontinued after four weeks for the 20
non responders (33.33%). A total of 179 patients including
the 20 non responders to 25mg sildenafil were placed on
50 mg sildenafil for four weeks. One hundred and fifty
seven patients (87.71%) had improved sexual function
and continued on the treatment for the duration of the
study period of sixteen weeks. Treatment was discontinued
in the 22 patients (12.29%) who reported no improvement
in sexual function after four weeks of therapy. All the 22
patients were placed on 100 mg sildenafil for a further
period of four weeks. In this group three patients (13.64%)
had improved sexual function and continued with the
therapy for sixteen weeks. The other 19 patients (86.64%)
were categorised as non responders to 25mg, 50mg and
l00mg of sildenafil therapy. Therefore in this study out of
the 219 patients who had various doses of sildenafil
therapy, 200 patients (91.32%) had improved erectile
function, orgasmic function and overall sexual satisfaction
(Table 5). These findings are similar to previous reports by
other investigators elsewhere(25,27-29).
The main adverse effects of viagra (sildenafil citrate)
administration recorded in this study included mild
headaches in (1.37%), dyspepsia in (0.91%), nausea and
vomiting in (0.46%) and facial flushing in (0.46%). These
adverse effects were mostly mild and transient and no
patient discontinued treatment during this study because
of the adverse effects. There were no episodes of myalgia,
visual disturbances or priapism. The adverse effects
reported in this study almost certainly reflect the presence
of phosphodiasterase type 5 in other tissues such as
platelets and vascular smooth muscles(30). These findings
indicate a high level of tolerability and acceptance of
sildenafil as has been previously reported by others(25,31).
Although oral sildenafil in the treatment of male
erectile dysfunction was only introduced recently in this
locality, it has proved to be an effective, well tolerated and
simple treatment for erectile dysfunction in the majority of
cases as has been previously reported by others(25,31).
However, the high cost of sildenafil which at present is
about ten US dollars per 50 mg tablet is bound to limit its
very much desired availability to a large number of
deserving patients in this locality.
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